Breaking Down Solid Tumors With Triumvira Immunologics' Dr. Paul Lammers
Source: Cell & Gene
![23_12_CGPodcast_1200x628_Ep67 23_12_CGPodcast_1200x628_Ep67](https://vertassets.blob.core.windows.net/image/7a95a94a/7a95a94a-2d95-4f2d-856d-74108c1af276/375_250-23_12_cgpodcast_1200x628_ep67.png)
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
This website uses cookies to ensure you get the best experience on our website. Learn more